Eli Lilly and Company (NYSE:LLY) Stock Position Trimmed by Los Angeles Capital Management LLC

Los Angeles Capital Management LLC cut its position in Eli Lilly and Company (NYSE:LLY) by 30.3% during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 433,548 shares of the company’s stock after selling 188,462 shares during the quarter. Eli Lilly and Company comprises 0.9% of Los Angeles Capital Management LLC’s holdings, making the stock its 18th biggest position. Los Angeles Capital Management LLC’s holdings in Eli Lilly and Company were worth $252,724,000 at the end of the most recent quarter.

Several other hedge funds have also recently bought and sold shares of the company. Simon Quick Advisors LLC increased its stake in Eli Lilly and Company by 10.5% during the 4th quarter. Simon Quick Advisors LLC now owns 2,927 shares of the company’s stock valued at $1,706,000 after buying an additional 278 shares during the period. Clear Harbor Asset Management LLC acquired a new position in shares of Eli Lilly and Company in the 4th quarter worth approximately $363,000. Terril Brothers Inc. grew its stake in shares of Eli Lilly and Company by 113.2% in the 4th quarter. Terril Brothers Inc. now owns 808 shares of the company’s stock worth $471,000 after purchasing an additional 429 shares during the last quarter. Hartline Investment Corp grew its stake in shares of Eli Lilly and Company by 1.1% in the 4th quarter. Hartline Investment Corp now owns 21,934 shares of the company’s stock worth $12,786,000 after purchasing an additional 248 shares during the last quarter. Finally, Meritage Portfolio Management increased its position in shares of Eli Lilly and Company by 23.4% in the fourth quarter. Meritage Portfolio Management now owns 6,377 shares of the company’s stock worth $3,717,000 after acquiring an additional 1,208 shares in the last quarter. 82.53% of the stock is currently owned by institutional investors.

Eli Lilly and Company Stock Performance

Shares of Eli Lilly and Company stock traded down $17.24 during trading on Thursday, reaching $759.51. The company’s stock had a trading volume of 1,778,760 shares, compared to its average volume of 3,052,224. The business’s 50-day moving average price is $762.03 and its 200-day moving average price is $669.96. The firm has a market cap of $721.66 billion, a PE ratio of 111.71, a P/E/G ratio of 1.58 and a beta of 0.37. Eli Lilly and Company has a 52 week low of $414.31 and a 52 week high of $800.78. The company has a quick ratio of 0.73, a current ratio of 0.94 and a debt-to-equity ratio of 1.69.

Eli Lilly and Company (NYSE:LLY) last announced its earnings results on Tuesday, April 30th. The company reported $2.58 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.53 by $0.05. The company had revenue of $8.77 billion during the quarter, compared to analysts’ expectations of $8.94 billion. Eli Lilly and Company had a net margin of 17.08% and a return on equity of 59.28%. Eli Lilly and Company’s quarterly revenue was up 26.0% on a year-over-year basis. During the same quarter in the previous year, the business posted $1.62 earnings per share. Equities analysts forecast that Eli Lilly and Company will post 13.5 earnings per share for the current year.

Wall Street Analyst Weigh In

Several research analysts have recently weighed in on the stock. The Goldman Sachs Group lifted their target price on shares of Eli Lilly and Company from $650.00 to $723.00 and gave the stock a “neutral” rating in a research report on Thursday, April 11th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $885.00 target price (up from $815.00) on shares of Eli Lilly and Company in a research note on Tuesday. Bank of America boosted their price objective on shares of Eli Lilly and Company from $800.00 to $1,000.00 and gave the stock a “buy” rating in a research note on Friday, March 1st. Erste Group Bank raised shares of Eli Lilly and Company from a “hold” rating to a “buy” rating in a report on Wednesday, April 3rd. Finally, JPMorgan Chase & Co. upped their target price on shares of Eli Lilly and Company from $850.00 to $900.00 and gave the company an “overweight” rating in a research note on Wednesday. Three investment analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $757.95.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.